These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1117 related items for PubMed ID: 19539111

  • 1. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
    Sohn HS, Lee TJ, Kim J, Kim D.
    Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation.
    Schonfeld W, Wang Cheng J, Tong KB, Seifeldin R.
    Clin Ther; 2008 May; 30(5):964-73. PubMed ID: 18555943
    [Abstract] [Full Text] [Related]

  • 3. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.
    van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, Bunin N, Wall DA, Hiemenz JW, Satoi Y, Lee JM, Walsh TJ, National Institute of Allergy and Infectious Diseases Mycoses Study Group.
    Clin Infect Dis; 2004 Nov 15; 39(10):1407-16. PubMed ID: 15546073
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness analysis of antifungal treatment for patients on chemotherapy.
    Nomura K, Kawasugi K, Morimoto T.
    Eur J Cancer Care (Engl); 2006 Mar 15; 15(1):44-50. PubMed ID: 16441676
    [Abstract] [Full Text] [Related]

  • 5. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
    Ziakas PD, Kourbeti IS, Mylonakis E.
    Clin Ther; 2014 Feb 01; 36(2):292-306.e1. PubMed ID: 24439393
    [Abstract] [Full Text] [Related]

  • 6. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.
    Koh LP, Kurup A, Goh YT, Fook-Chong SM, Tan PH.
    Am J Hematol; 2002 Dec 01; 71(4):260-7. PubMed ID: 12447954
    [Abstract] [Full Text] [Related]

  • 7. Antifungal prophylaxis with micafungin in patients treated for childhood cancer.
    Kusuki S, Hashii Y, Yoshida H, Takizawa S, Sato E, Tokimasa S, Ohta H, Ozono K.
    Pediatr Blood Cancer; 2009 Oct 01; 53(4):605-9. PubMed ID: 19533659
    [Abstract] [Full Text] [Related]

  • 8. De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections.
    Masterton RG, Casamayor M, Musingarimi P, van Engen A, Zinck R, Odufowora-Sita O, Odeyemi IA.
    J Med Econ; 2013 Nov 01; 16(11):1344-56. PubMed ID: 24003830
    [Abstract] [Full Text] [Related]

  • 9. Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant.
    Huang X, Chen H, Han M, Zou P, Wu D, Lai Y, Huang H, Chen X, Liu T, Zhu H, Wang J, Hu J.
    Biol Blood Marrow Transplant; 2012 Oct 01; 18(10):1509-16. PubMed ID: 22469884
    [Abstract] [Full Text] [Related]

  • 10. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients.
    Park S, Kim K, Jang JH, Kim SJ, Kim WS, Chung DR, Kang CI, Peck KR, Jung CW.
    J Infect; 2016 Nov 01; 73(5):496-505. PubMed ID: 27394404
    [Abstract] [Full Text] [Related]

  • 11. A cost and resource utilization analysis of micafungin bridging for hemato-oncological high-risk patients undergoing allogeneic stem cell transplantation.
    Heimann SM, Vehreschild MJ, Cornely OA, Franke B, von Bergwelt-Baildon M, Wisplinghoff H, Kron F, Scheid C, Vehreschild JJ.
    Eur J Haematol; 2015 Jun 01; 94(6):526-31. PubMed ID: 25310918
    [Abstract] [Full Text] [Related]

  • 12. Fluconazole as prophylaxis against fungal infection in patients with advanced HIV infection.
    Manfredi R, Mastroianni A, Coronado OV, Chiodo F.
    Arch Intern Med; 1997 Jan 13; 157(1):64-9. PubMed ID: 8996042
    [Abstract] [Full Text] [Related]

  • 13. Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts.
    McCoy D, Depestel DD, Carver PL.
    Pharmacotherapy; 2009 Nov 13; 29(11):1306-25. PubMed ID: 19857148
    [Abstract] [Full Text] [Related]

  • 14. [Cost benefit analysis for prophylactic use of itraconazole versus fluconazole after hematopoietic stem cell transplantation].
    Ota S, Wada A, Kosugi M, Matsuoka S, Asanuma S, Fujii S, Noguchi S, Nakata M, Imai K, Hirano T, Kobayashi N, Ogasawara M, Kiyama Y, Kasai M.
    Rinsho Ketsueki; 2010 Jan 13; 51(1):63-8. PubMed ID: 20134142
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation.
    Zilberberg MD, Kothari S, Shorr AF.
    Crit Care; 2009 Jan 13; 13(3):R94. PubMed ID: 19545361
    [Abstract] [Full Text] [Related]

  • 16. Choosing Optimal Antifungal Agents To Prevent Fungal Infections in Nonneutropenic Critically Ill Patients: Trial Sequential Analysis, Network Meta-analysis, and Pharmacoeconomic Analysis.
    Wang Y, Xie J, Xing Y, Chen L, Li Y, Meng T, Dong W, Wang X, Dong Y.
    Antimicrob Agents Chemother; 2017 Dec 13; 61(12):. PubMed ID: 28993334
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant.
    Hiemenz J, Cagnoni P, Simpson D, Devine S, Chao N, Keirns J, Lau W, Facklam D, Buell D.
    Antimicrob Agents Chemother; 2005 Apr 13; 49(4):1331-6. PubMed ID: 15793107
    [Abstract] [Full Text] [Related]

  • 18. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature.
    Wilke M.
    Eur J Med Res; 2011 Apr 28; 16(4):180-6. PubMed ID: 21486732
    [Abstract] [Full Text] [Related]

  • 19. Micafungin as antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: results of different dosage levels in clinical practice.
    Langebrake C, Rohde H, Lellek H, Wolschke C, Kröger NM.
    Clin Transplant; 2014 Mar 28; 28(3):286-91. PubMed ID: 24479680
    [Abstract] [Full Text] [Related]

  • 20. [Cost effectiveness of posaconazole versus fluconazole/itraconazole in the prophylactic treatment of invasive fungal infections in Mexico].
    Rely K, Alexandre PK, Escudero GS.
    Value Health; 2011 Mar 28; 14(5 Suppl 1):S39-42. PubMed ID: 21839897
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.